ScholarIQanswers from OpenAlex
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
PaperCitations, authors & open-access status
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma have?
ScholarIQcitation count
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma has 8,284 citations in the OpenAlex counts ScholarIQ stores.
When was Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma published?
ScholarIQyear
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma has 2009 year in the ScholarIQ index.
What is the open-access status of Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma?
ScholarIQoa status
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma has bronze oa status in the ScholarIQ index.
What is the DOI of Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma?
ScholarIQdoi
The DOI for Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma is on the source record.
What is the PMID of Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma?
ScholarIQpmid
The PMID for Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma is on the source record.
What is the OpenAlex record for Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma?
ScholarIQopenalex
The OpenAlex for Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma is on the source record.